Furthermore, in ER + and Her2/neu + breast cancers, drug-resistant phenotypes that emerge following receptor-targeted therapies are believed to be dependent on Notch signaling for continued survival and proliferation [12, 13]. The gene discussed is ERBB2; the disease is breast cancer.